Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 12.24 -0.60 (-4.67%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Travere Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights March 13, 2024 Via Benzinga Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN) March 11, 2024 Submission is based on 2-year confirmatory results from the Phase 3 PROTECT Study in which FILSPARI demonstrated a significant reduction in proteinuria, preservation of kidney function and a generally... From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences February 26, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings) February 16, 2024 Via Benzinga Earnings Scheduled For February 15, 2024 February 15, 2024 Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. Via Benzinga Earnings Preview For Travere Therapeutics February 14, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics January 18, 2024 Via Benzinga Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy February 23, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results February 15, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results February 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Where Travere Therapeutics Stands With Analysts December 15, 2023 Via Benzinga What's Going On With Travere Therapeutics Stock? December 05, 2023 Travere Therapeutics, Inc. (NASDAQ: TVTX) shares are trading higher Tuesday. Via Benzinga Travere Therapeutics Inc. (NASDAQ: TVTX) Near the Top of Equities by Percentage Gain on 12/5 December 05, 2023 Via Investor Brand Network Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference February 01, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations January 25, 2024 Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA nephropathy in Japan From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Provides Corporate Update and 2024 Outlook January 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Where Travere Therapeutics Stands With Analysts November 20, 2023 Via Benzinga Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug December 21, 2023 The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... Via Benzinga Exposures Product Safety Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU) December 14, 2023 Potential for pegtibatinase to become first disease-modifying treatment for classical HCU; topline data expected in 2026 From Travere Therapeutics, Inc. Via GlobeNewswire THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday December 06, 2023 U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday. Via Benzinga Topics Stocks Exposures US Equities Crude Oil Moves Lower; AutoZone Profit Tops Views December 05, 2023 U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session December 05, 2023 Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session December 05, 2023 Via Benzinga NIO Reports Q3 Results, Joins Hovnanian Enterprises, Signet Jewelers And Other Big Stocks Moving Higher On Tuesday December 05, 2023 U.S. stocks traded mostly lower, with the Dow Jones index falling more than 100 points on Tuesday. Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Monday's After-Market Session December 04, 2023 Via Benzinga Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS December 04, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference November 21, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Third Quarter 2023 Financial Results November 07, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Earnings Scheduled For November 7, 2023 November 07, 2023 Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.